Trial Reaches Final Phase With Promising Signs For Untreatable Blindness
Until now there has been no cure for the age-related macular degeneration (AMD), but now clinical trails have come up with some signs of promise.
In UK alone around 500,000 people above the age of 50 are affected with this most common form of macular degeneration.
Eye experts in Southampton are leading the trails and it is in the final phase. Lampalizumab injections are being given to the patients at Southampton General Hospital who have lost some eye sight due to geographic atrophy (GA), which is known to be an advanced form of dry AMD.
According to the researchers, the experimental drug showed promise in earlier trials and is believed in 20 percent of the participant patients it could reduce the area of damage.
Professor of ophthalmology at the University of Southampton, Andrew Lotery, said: “Lampalizumab has already been shown to reduce damage caused by GA by 20% in most cases and, for some patients with a specific genetic bio marker, by up to 44% in early-stage trials. 
“These are significant reductions and, if they are replicated in this larger study, it will revolutionize the way we treat the condition and mean patients are no longer condemned to blindness when diagnosed.”
Usually at higher age the cells in the part of the eye that is responsible for vision gets damaged by the waste deposits called drusen. This result with either progressive or permanent loss of vision……
Read more:
Source: Pierce Pioneer